Following a six-month review, Teva Pharmaceuticals Industries Ltd.'s new management is drawing a clean line with the company's past by refocusing R&D investment on key growth drivers in complex and combination generics and branded CNS and respiratory drugs.

President and CEO Jeremy Levin and CSO and President of Global R&D Michael Hayden detailed these growth drivers for BioCentury in advance of unveiling the company's new strategy at an investor meeting on Dec. 11.